articleThe Lancet OncologySep 17, 2012Closed access

Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

Université Paris-Sud · Institut Gustave Roussy · +14 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,382
total citations
FWCI
94.87
Percentile
100%
References
40
Citations per year

Authors

18

Topics & keywords

Keywords
  • Abiraterone acetate
  • Medicine
  • Placebo
  • Prednisone
  • Prostate cancer
  • Clinical endpoint
  • Interim analysis
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding